Patents by Inventor Elin Martina POLA

Elin Martina POLA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSION PROTEINS COMPRISING MODIFIED ALPHA VIRUS SURFACE GLYCOPROTEINS AND TUMOR ASSOCIATED ANTIGEN AND METHODS THEREOF
    Publication number: 20230181706
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Application
    Filed: October 13, 2022
    Publication date: June 15, 2023
    Inventors: Peter LEONARDI, Elin Martina POLA, Jeffrey BABAD
  • Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
    Patent number: 11471518
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: October 18, 2022
    Assignee: OMNICYTE
    Inventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad
  • FUSION PROTEINS COMPRISING MODIFIED ALPHA VIRUS SURFACE GLYCOPROTEINS AND TUMOR ASSOCIATED ANTIGEN AND METHODS THEREOF
    Publication number: 20210077600
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Application
    Filed: April 9, 2020
    Publication date: March 18, 2021
    Inventors: Peter LEONARDI, Elin Martina POLA, Jeffrey BABAD
  • Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
    Patent number: 10660948
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 26, 2020
    Assignee: OMNICYTE
    Inventors: Peter Leonardi, Elin Martina Pola, Jeffrey Babad
  • FUSION PROTEINS COMPRISING MODIFIED ALPHA VIRUS SURFACE GLYCOPROTEINS AND TUMOR ASSOCIATED ANTIGEN AND METHODS THEREOF
    Publication number: 20180243389
    Abstract: The present disclosure relates to fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more tumor specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins and one or more viral specific antigens. Also disclosed are fusion proteins that comprise one or more modified alpha virus surface glycoproteins. It also relates to methods to activate the immune system in cancer patients to infiltrate and kill tumor cells or cells infected with a latent virus. The present disclosure provides a platform technology that elicits a faster, broader and stronger immune response using the fusion proteins.
    Type: Application
    Filed: March 18, 2016
    Publication date: August 30, 2018
    Inventors: Peter LEONARDI, Elin Martina POLA, Jeffrey BABAD